Fibrinogen reimbursement and its effect on heart surgery recovery
Part of Heart & circulation clinical trials.
This study looks back at patient records from heart surgeries that used a heart-lung machine to see how the availability of a medicine called fibrinogen affected blood transfusions and recovery. It helps us understand if wider access to this treatment improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your heart surgery must have been complex and done with a heart-lung bypass machine.
- Complex heart surgery includes procedures like bypass surgery combined with valve repair or replacement, replacing two or more heart valves, repeat heart surgery, surgery for heart infections, or surgery on the aorta.
- The surgery must have taken place between January 1, 2016, and December 31, 2024.
- You must not have been pregnant at the time of surgery, and you must not have needed an ECMO (a machine that takes over heart and lung function) after surgery.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how blood cells change during heart surgery and whether these changes affect bleeding or inflammation after the operation. It may help doctors predict and manage complications in people having heart surgery.
This study looks at how much donated blood (blood products) is needed for younger adults during heart surgery that uses a heart-lung machine. It may help doctors choose safer, more appropriate blood-saving plans for people like you.
This study tests whether giving blood transfusions based on each patient's needs during and after heart surgery is safe and effective. It compares different transfusion thresholds to see which works better.
This trial tests whether giving a personalized dose of fibrinogen, a protein that helps blood clot, after heart surgery reduces bleeding and the need for blood transfusions. It aims to improve recovery for patients who need fibrinogen after being on a heart-lung machine.
This trial is for hospitals, not patients. Hospitals that do many open heart surgeries and whose doctors agree to use certain bleeding control drugs (fibrinolysis inhibitors) as per the study protocol can participate.
This trial compares two treatments for bleeding after heart surgery: a medicine called FEIBA (which helps blood clot) and fresh frozen plasma (a blood product). The goal is to see which works better as a first treatment for bleeding during recovery.
Hear when a new Cardiac Surgery trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.